Cardiol Therapeutics (CRDL) vs Humacyte (HUMA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cardiol Therapeutics (CRDL) has outperformed Humacyte (HUMA) over the past year, losing 11.3% versus a loss of 63.5%. Over five years, CRDL leads with a -60.1% price change compared with -95.9% for HUMA. Humacyte is the larger company by market cap ($123.7 million vs $110.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CRDL | HUMA |
|---|---|---|
| Share price | $0.8626 | $0.4454 |
| Market cap | $110.14M | $123.73M |
| 1-day change | -2.28% | -17.90% |
| YTD return | -9.58% | -53.65% |
| 1-year return | -11.35% | -63.49% |
| 5-year return | -60.06% | -95.94% |
| EPS (TTM) | $-0.24 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $2.04M |
| Net income (latest FY) | — | $-40.83M |
| Gross margin | — | -376.05% |
| Operating margin | — | -5306.04% |
| Net margin | — | -2003.58% |
| 52-week high | $2.34 | $1.53 |
| 52-week low | $0.8417 | $0.337 |
| Distance from 52-week high | -63.14% | -70.79% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +874.96% | +268.21% |
| Average volume | 1.20M | 5.36M |
| Shares outstanding | 127.69M | 277.80M |
| Employees | 18 | 184 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CRDL has outperformed HUMA by 52.1 percentage points over the past year.
About Cardiol Therapeutics
CRDL stock →Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product candidate is CardiolRx, which is in Phase III multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
CRDL vs HUMA FAQ
Which is bigger, Cardiol Therapeutics or Humacyte?
Humacyte (HUMA) is larger, with a market capitalization of $123.73M compared with $110.14M for Cardiol Therapeutics (CRDL).
Which stock has performed better over the past year, CRDL or HUMA?
CRDL returned -11.35% over the past 12 months, compared with -63.49% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Cardiol Therapeutics and Humacyte in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.